COPD Monitoring Research

Living with COPD?
Know Your Biological Age

GrimAge predicts COPD outcomes better than traditional lung function tests. Our study helps you track disease progression and response to treatment.

Lung Disease Focus
Predict Outcomes
Track Progression
COPD & Biological Aging
Research findings
5-10 years
Average GrimAge acceleration in COPD patients
2-3x
Better mortality prediction vs FEV1 alone
Modifiable
Smoking cessation & exercise can improve scores

Based on COPD cohort studies and meta-analyses

Beyond Spirometry

Lung function tests only tell part of the story. COPD is a systemic disease that ages your entire body - and GrimAge captures this.

Systemic Inflammation

COPD causes body-wide inflammation that accelerates aging in the heart, brain, and metabolic systems - not just the lungs.

Smoking Legacy

GrimAge includes DNAm Pack Years - it directly measures the epigenetic signature of smoking damage even after quitting.

Comorbidity Risk

COPD patients have elevated risk of heart disease, diabetes, and cognitive decline - GrimAge predicts these better than FEV1.

Pulmonology Research

Why GrimAge for COPD?

Traditional measures like FEV1 capture lung damage but miss the systemic aging that drives COPD mortality. GrimAge fills this gap.

Superior Mortality Prediction

GrimAge predicts COPD mortality better than spirometry alone

Captures Smoking Damage

DNAm Pack Years component specifically measures smoking's epigenetic legacy

Exacerbation Risk

Higher GrimAge acceleration predicts more frequent COPD exacerbations

Track Interventions

Monitor whether pulmonary rehab and lifestyle changes affect biological age

What You'll Get From the Study

Comprehensive biological age monitoring designed for COPD patients

GrimAge Analysis

Full epigenetic clock with COPD-specific component breakdown

Smoking Impact

DNAm Pack Years quantifies epigenetic smoking damage

Inflammation Profile

Track systemic inflammation beyond lung-specific markers

Progress Tracking

Monitor improvements from rehab and lifestyle changes

COPD Research Initiative

Your Lungs Tell Part of the Story. GrimAge Tells the Rest.

Join our study to understand the full biological impact of COPD - and track your progress beyond FEV1.

Study Eligibility

  • Adults (40+) with diagnosed COPD (any stage)
  • Current or former smokers (or other COPD causes)
  • Willing to provide blood samples at baseline and 6 months
  • Interested in comprehensive health monitoring
Check Eligibility & Enroll

Private & secure. Your health data remains confidential.

Working With Pulmonary Health Organizations

COPD Foundation
American Lung Association
ATS
GOLD

Partnering with respiratory health advocacy groups

Frequently Asked Questions

How is GrimAge different from lung function tests?

Spirometry measures airflow limitation in your lungs. GrimAge measures biological aging across your entire body, including the systemic effects of COPD like inflammation and cardiovascular risk. They complement each other - GrimAge adds the "big picture" to spirometry's lung focus.

Can quitting smoking improve my GrimAge?

Smoking cessation stops adding new epigenetic damage, but some changes persist. However, the inflammation and other factors that contribute to GrimAge can improve with cessation, exercise, and proper COPD management. Tracking GrimAge over time shows these improvements.

Does pulmonary rehabilitation affect biological age?

Early research suggests that exercise and pulmonary rehab can improve epigenetic aging markers. This is one of the questions our study aims to answer definitively for COPD patients.

What COPD stages are eligible?

All GOLD stages (I-IV) are eligible. In fact, we're particularly interested in comparing biological age across different disease stages to understand how GrimAge changes with COPD progression.

Will my results be shared with my pulmonologist?

That's your choice. We provide comprehensive reports that you can share with your healthcare team if you wish. Many patients find it valuable to discuss their biological age with their pulmonologist as part of comprehensive COPD management.